Inhibikase Therapeutics (IKT) Share-based Compensation Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -8.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,486.54% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -22.43% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -4.01% |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | 27.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.02% |
| Mar 31, 2026 | 172.24% |
| Dec 31, 2025 | -42.67% |
| Sep 30, 2025 | 2,957.08% |
| Jun 30, 2025 | 13,610.60% |
| Mar 31, 2025 | 3,721.90% |
| Dec 31, 2024 | 6,369.14% |
| Sep 30, 2024 | 14.06% |
| Jun 30, 2024 | -75.41% |
| Mar 31, 2024 | -56.65% |
| Dec 31, 2023 | 21.81% |
| Sep 30, 2023 | 27.50% |
| Jun 30, 2023 | -5.97% |
| Mar 31, 2023 | 0.04% |
| Dec 31, 2022 | -62.25% |
| Sep 30, 2022 | -71.12% |
| Jun 30, 2022 | -58.83% |
| Mar 31, 2022 | -79.15% |
| Dec 31, 2021 | 163.41% |
| Sep 30, 2021 | 152.16% |